Risankizumab for the Treatment of Moderate-to-Severe Psoriasis: Real-Life Multicenter Experience from the Czech Republic

• DOI: 10.1007/s13555-021-00556-2
• Publication Date: 2021-06-05T15:02:54Z
• Authors: Spyridon Gkalpaki...; Petra Cetkovska; Petr Arenberger; Tomas Dolezal; Monika Arenbergerova; Barbora Velackova; Jorga Fialova; Martina Kojanova
• Keywords: 03 medical and health sciences; 0302 clinical medicine; Original Research; 3. Good health

Risankizumab has been approved for the treatment of moderate-to-severe plaque psoriasis; however, real-life data are limited. Our objectives were to evaluate effectiveness and safety risankizumab its impact on quality life patients with psoriasis in a real-world setting. We retrospectively analyzed 154 from 18 centers Czech Republic who had undergone biologic therapy psoriasis. Baseline characteristics included comorbidities, demographics, previous therapies, Dermatology Life Quality Index (DLQI) score, Psoriasis Area Severity (PASI) score. The proportion achieving 90% improvement their PASI score baseline (PASI 90) complete resolution 100) after 16, 28, 52 weeks was analyzed. A total 95 men 59 women mean body mass index (BMI) 29.6 enrolled our analysis. age 48.5 years time diagnosis until initiation 22.5 years. After 16 weeks, 63.8 44.7% achieved 90 100 responses, respectively. Improvement continued time, responses increased 82.4 67.6%, respectively, at week 52. significant reduction observed over DLQI. Patients response higher DLQI than those (− 15.9 vs. − 11.8). independent BMI therapy. No new issues identified. In this patient population, effective safe setting, high number responses. seen response, which supports evidence that value should be therapeutic goal.